All News
Infertility in women with RA 2x higher
Risk factors
- age
- disease activity
- use of NSAIDs
- use of pred >7.5mg/day
With T2T aiming for remission, fertility improves and becomes similar to the general population
#ACR24 @RheumNow ABST#1647 https://t.co/B2Tx4dju4Z
Jiha Lee JihaRheum ( View Tweet)
John Stone
Steroid-free AAV
CYCLOPS: steroid tox like “wallpaper on room”
WGET (ETN for GCA) - taper off by 6 mos - neg trial but started tapers
RAVE - low doses 8-9 mg/d over 18 mos
LoVAS - low dose steroid equally eff
ADVOCATE - AVA one month taper, tox score
#ACR24 @RheumNow https://t.co/C7eLK5UNPM
Eric Dein ericdeinmd ( View Tweet)
Biosimilar changes
ASP outpacing reimbursement making not affordable to use
Working with CMS but needs further legislation to fix this
FDA may change interchangeability status for medications to no longer require switching studies
@ACRheumDC @RheumNow #ACR24 https://t.co/daYQJvsHRG
Eric Dein ericdeinmd ( View Tweet)
Regulatory update @ACRheumDC
Inflation Reduction
Planned decrease in 10 drug prices including ETN
Expect this may be gutted by new administration. Will follow and advocate for drug pricing
@RheumNow #ACR24 https://t.co/ZrcMaLD6tu
Eric Dein ericdeinmd ( View Tweet)
#Blinded by results? 😊
#Ocular #involvement in #GPA
👇
Helped by #rituximab
👁️ #GPA
Difficult
Proptosis
Pseudotumour
Conjunctivitis
Scleritis
Vasculitis
Ocular muscles - diplopia
Small case series ‘author defined’ remission in
80% 👍 #RTX
#abst0726 @rheumnow #ACR24 https://t.co/GHptelOTyv
Janet Pope Janetbirdope ( View Tweet)
Managing DMARDs in pregnancy. Curbside consults by Lisa Sammaritano @RheumNow #ACR24 https://t.co/FQrLNz4yCz
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
@KDAO2011 help me out here; what is the point of analyses like this?
NO difference in PROs comparing voclo vs plbo...
...but if you split by responder status its different
Prescribing the drug doesn't help PROs, but when it works it works? 🤔
#ACR @RheumNow Abstr#1538 https://t.co/339drHwUuK
Mike Putman EBRheum ( View Tweet)
ACR 2024 - Day 1 Report
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
Read Article
#ACR 2024 BEST Abstracts from Day 1
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC. Here are some of the best abstracts from Saturday Nov. 16th.
Read Article
Difficult to Manage Axial Spondyloarthritis
Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.
Read Article
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/DZrM5aQpJ7 https://t.co/CkGP6H8J6x
Dr. John Cush RheumNow ( View Tweet)
New data to guide role of long-term, low dose GC in GPA
Active GPA s/p tx -> randomized to d/c pred within 1 mo or stay on 5mg daily
Fewer relapses on 5mg pred but w/qualifications:
👉 most flares = minor
👉 no difference in flares if RTX on board
@RheumNow #ACR24 Abst 0774 https://t.co/Jvc40QWLqM
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Richard Conway RichardPAConway ( View Tweet)
Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Richard Conway RichardPAConway ( View Tweet)
Abstract #0805
Data from OTIS Registry shows Certolizumab pegol (Cimzia) exposure during pregnancy was not associated with increased risk of major birth defects, structural defects, or adverse pregnancy outcomes. #ACR24 @RheumNow
Akhil Sood MD AkhilSoodMD ( View Tweet)
What's the assoc between RA disease activity & ILD?
Results @MassGenBrigham show early active RA is assoc with
➡️6x incr risk of #ILD
➡️4x incr risk of RA-related lung disease
Early DMARDs are vital to reduce articular & extra-articular manifestations!
Ab0802 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
❔Can rheum drugs have beneficial effects on cognition?
💊Possible benefits with MTX and TNFis but certainly an active area of research and more studies needed
#ACR24 @RheumNow https://t.co/lCnIRLwNjK
Mrinalini Dey DrMiniDey ( View Tweet)
Ab#0458 #ACR24
10 year outcomes of 176 patients with seroneg RA
32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1)
40 (23%) had drug-free remission
30 (17%) started b/tsDMARD
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE
Richard Conway RichardPAConway ( View Tweet)